neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part II.
Pritchard
Kathleen I
KI
Levine
Mark N
MN
Tu
Dongsheng
D
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005819:Genetic Markers; D006801:Humans; D010052:Ovariectomy; D017697:Premenopause; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000096:biosynthesis*; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D005819:Genetic Markers; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen